CDK9-IN-1 Inhibitor

Name: CDK9-IN-1 Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5752891
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5752891

CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment,of HIV infection (IC50: 39nM for CDK9/CycT1). More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

CDK9-IN-1, Inhibitor

Full Product Name

CDK9-IN-1

Product Gene Name

CDK9-IN-1, inhibitor

Form/Format

Solid. Powder

Purity/Purification

98.00%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

499.54

Solubility

DMSO: 25mg/mL (50.05mM) Need ultrasonic
H2O: <0.1mg/mL (insoluble)
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C26H21N5O4S

SMILES

CC1=C(NS(C)(=O)=O)C=C(NC2=NC=NC(C3=CC=CC(N4C(C5=C(C=CC=C5)C4=O)=O)=C3)=C2)C=C1

CAS Number

1415559-43-1

Target & IC50

CDK9/CycT1: ic50 39nM

Product Categories/Family for CDK9-IN-1, inhibitor

Cell Cycle/Checkpoint; CDK

Product References and Citations for CDK9-IN-1, inhibitor

Nemeth G, et al. Novel, selective CDK9 inhibitors for the treatment,of HIV infection. Curr Med Chem. 2011;18(3):342-358.
Nemeth G, et al. Novel, selective CDK9 inhibitors for the treatment,of HIV infection. Curr Med Chem. 2011;18(3):342-358.

Other Notes

Small volumes of CDK9-IN-1, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for CDK9-IN-1 purchase

MBS5752891 is an inhibitor targeting CDK9-IN-1.